Shares of Sigachi Industries Ltd could be in focus after the company announced a key strategic development on Monday. The company’s wholly-owned subsidiary, Sigachi MENA FZCO, has signed a Memorandum of Understanding (MoU) with Czech Republic-based Respilon Group s.r.o. to collaborate on advancing nanofiber-based drug delivery technologies.
Under the agreement, Sigachi and Respilon will jointly develop, manufacture, and commercialize drug delivery solutions based on Respilon’s proprietary NUENEX® nanofiber technology. This partnership focuses on creating next-generation pharmaceutical delivery formats like the Invisible Patch and Powder-based formulations, which aim to improve therapeutic outcomes and elevate the patient experience through non-invasive, precision drug delivery.
The MoU was signed on April 24, 2025, between Mr. Lijo Chacko, Managing Director of Sigachi MENA FZCO, and Mr. Roman Zima, Chief Business Officer of Respilon Group, during a formal ceremony.
Key highlights of the collaboration:
-
Focus on developing Invisible Patch and powder-based drug delivery systems.
-
Commercialization strategies to be built around nanofiber encapsulation technology for APIs and formulations.
-
Strengthening Sigachi’s global presence in advanced drug delivery technologies.
Commenting on the development, Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries, said, “Partnering with Respilon aligns perfectly with our vision to deliver next-generation pharmaceutical solutions that improve therapeutic outcomes and elevate the patient experience.”
Mr. Roman Zima of Respilon also expressed optimism, stating that Sigachi’s deep industry expertise and global reach would accelerate the deployment of NUENEX® technology across pharmaceutical markets worldwide.
About Sigachi Industries:
Sigachi is a global player specializing in Active Pharmaceutical Ingredients (APIs), excipients, vitamin-mineral blends, and nutraceutical solutions, with manufacturing units across Telangana, Gujarat, and Karnataka. It operates in over 65 countries and has subsidiaries in the UAE and USA.
About Respilon Group:
Respilon, headquartered in the Czech Republic, specializes in nanofiber applications across health protection and pharmaceutical sectors, and operates in more than 46 countries.
Disclaimer: This article contains forward-looking statements based on current expectations. Actual results may differ due to risks and uncertainties.
